Krystal Biotech Announces Virtual Presentation Of Pre-clinical Data On KB408 For The Treatment Of Alpha-1 Antitrypsin Deficiency At ESGCT
Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary
Krystal Biotech To Present Data On DEB And B-VEC At DEBRA International Conference 2021
Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present data on its lead product candidate beremagene geperpavec
Krystal Biotech Q2 EPS $(0.74) Down From $(0.37) YoY
Krystal Biotech (NASDAQ:KRYS) reported quarterly losses of $(0.74) per share. This is a 100 percent decrease over losses of $(0.37) per share from the same period last year.
10 Biggest Price Target Changes For Tuesday
Citigroup boosted International Business Machines Corporation (NYSE: IBM) price target from $140 to $150. IBM shares rose 4% to $143.41 in pre-market trading.
Goldman Sachs Upgrades Krystal Biotech to Buy, Raises Price Target to $90
Goldman Sachs analyst Madhu Kumar upgrades Krystal Biotech (NASDAQ:KRYS) from Neutral to Buy and raises the price target from $73 to $90.
Krystal Biotech’s KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin Condition
Krystal Biotech Inc (NASDAQ:KRYS) announced updated results from the Phase 1/2 trial evaluating topical administration of KB105 in patients with autosomal…
The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), the leader in redosable gene therapies for rare diseases, today announced updated results from the Phase 1/2 clinical trial evaluating topical administration